Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis
Top Cited Papers
Open Access
- 17 January 2025
- journal article
- research article
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (5) , 1977-1985
Abstract
Objective: Tofersen, an antisense oligonucleotide, has recently received FDA and EMA approval for treating amyotrophic lateral sclerosis (ALS) in adults with SOD1 gene mutations. This systematic review and meta-analysis synthesized evidence on tofersen’s safety and efficacy in patients with SOD1-related ALS. Methods: A comprehensive search of three databases was conducted from inception through October 2024. Eligible studies included clinical trials, observational studies, and case studies. Meta-analyses were conducted using a random-effects model in RevMan. Results: Twelve studies involving 195 patients treated with tofersen met the inclusion criteria, comprising two randomized controlled trials (RCTs), five cohort studies, one case series, and four case reports. Tofersen demonstrated promising effects, notably reducing SOD1 levels in cerebrospinal fluid and neurofilament light chain (NfL) in plasma, a biomarker strongly correlated with ALS progression and survival. Meta-analysis of RCTs showed a significantly lower rate of decline in ALS Functional Rating Scale-Revised (ALSFRS-R) scores from baseline in the tofersen group compared to placebo (SMD = 0.44, 95% CI [0.05 to 0.83], P = 0.03) and a significant reduction in the decline of predicted Slow Vital Capacity (P = 0.005). In a pre-post meta-analysis of five studies, a significant decrease in ALS progression rate (ALSFRS-R decline rate) was observed (MD = -0.28, 95% CI [-0.40 to -0.15], P < 0.0001). Reported adverse events were consistent with ALS progression or procedural effects. Conclusion: Current evidence suggests that tofersen effectively reduces SOD1 and NfL levels and slow disease progression in SOD1 ALS, showing promise as a targeted therapeutic option.Keywords
Funding Information
- Minufiya University
This publication has 32 references indexed in Scilit:
- Exploiting the role of CSF NfL, CHIT1, and miR-181b as potential diagnostic and prognostic biomarkers for ALSJournal of Neurology, 2024
- Changes in Cerebrospinal Fluid Concentrations of Selenium Species Induced by Tofersen Administration in Subjects with Amyotrophic Lateral Sclerosis Carrying SOD1 Gene MutationsBiological Trace Element Research, 2024
- Clinical and patient‐reported outcomes and neurofilament response during tofersen treatment in SOD1‐related ALS—A multicenter observational study over 18 monthsMuscle & Nerve, 2024
- Long-term treatment of SOD1 ALS with tofersen: a multicentre experience in 17 patientsJournal of Neurology, 2024
- Effects of tofersen treatment in patients with SOD1-ALS in a “real-world” setting – a 12-month multicenter cohort study from the German early access programeClinicalMedicine, 2024
- Myelitis as a side effect of tofersen therapy in SOD1-associated ALSJournal of Neurology, 2023
- Selective removal of misfolded SOD1 delays disease onset in a mouse model of amyotrophic lateral sclerosisCellular and Molecular Life Sciences, 2023
- Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in SOD1‐related ALS: Treatment experience in clinical practiceMuscle & Nerve, 2023
- Treatment of a Mouse Model of ALS by In Vivo Base EditingMolecular Therapy, 2020
- Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutationsAnnals of Neurology, 2017